Progression of RAS-mutant leukemia during RAF inhibitor treatment.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  New England Journal of Medicine

• Publication date

  2012-12-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1208958PMID 23134356PMCID PMC3627494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

  2013cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

  2012cited by this paper
• Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

  2012cited by this paper
• RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• RAF inhibition and induction of cutaneous squamous cell carcinoma

  2011cited by this paper
• Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

  2011cited by this paper
• Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

  2010cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Paradoxical activation of Raf by a novel Raf inhibitor.

  1999cited by this paper
• RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.

  1990cited by this paper
• RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia

  1990cited by this paper

• Chronic myelomonocytic leukaemia occurring in patients with pulmonary Langerhans cell histiocytosis: A common progenitor?

  2025cites this paper
• Recent advances in therapeutic strategies of Erdheim-Chester disease

  2025cites this paper
• Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation

  2025cites this paper
• BRAF — a tumour-agnostic drug target with lineage-specific dependencies

  2024cites this paper
• Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

  2024cites this paper
• Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers

  2024cites this paper
• Tumor biomarkers for diagnosis, prognosis and targeted therapy

  2024cites this paper
• Enzyme Is the Name—Adapter Is the Game

  2024cites this paper
• Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma

  2024cites this paper
• Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice

  2024cites this paper
• Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies

  2024cites this paper
• The oncogenic potential of Rab-like protein 1A (RBEL1A) GTPase: The first review of RBEL1A research with future research directions and challenges

  2023cites this paper
• RAS‐targeted cancer therapy: Advances in drugging specific mutations

  2023cites this paper
• A twenty year perspective on melanoma therapy

  2023cites this paper
• The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer

  2022cites this paper
• A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

  2022cites this paper
• Development of a potent small‐molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation

  2022cites this paper
• Identification of cell type–specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors

  2022cites this paper
• 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie

  2022cites this paper
• Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies

  2022cites this paper
• Diagnosis of Hairy Cell Leukemia and HCL-like Disorders: Pitfalls to Avoid and the need to Integrate Molecular Data

  2022cites this paper
• Leucémie à tricholeucocytes et autres proliférations à cellules chevelues

  2022cites this paper
• Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia

  2022cites this paper
• Complications following novel therapies for non‐small cell lung cancer

  2022cites this paper
• How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

  2022cites this paper
• [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?]

  2021cites this paper
• Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib- resistant mast cell leukemia

  2021cites this paper
• Case Report: Opposite Effects of BRAF Inhibition on Closely Related Clonal Myeloid Disorders

  2021cites this paper
• Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment

  2021cites this paper
• RAF-MEK-ERK pathway in cancer evolution and treatment.

  2021cites this paper
• Clinical cancer genomic profiling

  2021cites this paper
• The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma

  2021cites this paper
• 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie

  2021cites this paper
• Vemurafenib drives EMT gene expression in BRAFi-resistant BRAFV600E/NRASQ61K melanoma enhancing tumor growth and metastasis in a bioluminescent murine model.

  2021cites this paper
• Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation

  2020cites this paper
• Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia

  2020cites this paper
• Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling

  2020cites this paper
• Current State of Target Treatment in BRAF Mutated Melanoma

  2020cites this paper
• Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View

  2020cites this paper
• The Emerging Role of Ras Pathway Signaling in Pediatric Cancer

  2020cites this paper
• Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib

  2020cites this paper
• Biology and Treatment of Hairy Cell Leukemia

  2020cites this paper
• Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.

  2020cites this paper
• Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors

  2020cites this paper
• Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

  2020cites this paper
• Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

  2019cites this paper
• BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS

  2019cites this paper
• Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy

  2019cites this paper
• Advancements in MAPK signaling pathways and MAPK‐targeted therapies for ameloblastoma: A review

  2019cites this paper
• BRAF in the cross-hairs

  2019cites this paper
• Hairy cell leukemia 2018 Update on diagnosis, risk-stratification, and treatment

  2019cites this paper
• Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

  2019cites this paper
• Dual blockage of STAT3 and ERK1/2 eliminates radioresistant GBM cells

  2019cites this paper
• Histiocytic Disorders

  2018cites this paper
• Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond

  2018cites this paper
• MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT‐737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

  2018cites this paper
• Erdheim-Chester Disease

  2018cites this paper
• Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia

  2018cites this paper
• Hyperprogressive disease: recognizing a novel pattern to improve patient management

  2018cites this paper
• Therapeutic strategies to target RAS-mutant cancers

  2018cites this paper
• Targeting the MAPK Pathway in RAS Mutant Cancers.

  2018cites this paper
• Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.

  2018cites this paper
• Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy

  2018cites this paper
• Targeted Therapies for BRAF-Mutant Metastatic Melanoma

  2018cites this paper
• Clinical update on K-Ras targeted therapy in gastrointestinal cancers.

  2018cites this paper
• High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

  2017cites this paper
• Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

  2017cites this paper
• Adjuvant Melanoma Therapy - Head-Spinning Progress.

  2017cites this paper
• Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

  2017cites this paper
• Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells

  2017cites this paper
• Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

  2017cites this paper
• Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

  2017cites this paper
• Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.

  2017cites this paper
• Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.

  2017cites this paper
• Overcoming resistance to BRAF inhibitors.

  2017cites this paper
• Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

  2017cites this paper
• Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

  2017cites this paper
• Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

  2017cites this paper
• The Many Faces of the Paradoxical Response to BRAF Inhibitors

  2017cites this paper
• Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

  2017cites this paper
• BRAF inhibitor‐associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management

  2017cites this paper
• Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia.

  2017cites this paper
• Advances in potential targeted therapies for Erdheim-Chester disease

  2017cites this paper
• BRAF inhibitor treatment of melanoma causing colonic polyps: An alternative hypothesis

  2017cites this paper
• Rôle du récepteur des xénobiotiques PXR (Pregnane X Receptor) et de ses gènes cibles sur la sensibilité des lignées de cancer de prostate aux inhibiteurs de kinases

  2017cites this paper
• Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy

  2017cites this paper
• Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition

  2017cites this paper
• Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment

  2017cites this paper
• Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies.

  2017cites this paper
• PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

  2017cites this paper
• Systemic Therapy Options for Patients With Unresectable Melanoma.

  2017cites this paper
• Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.

  2017cites this paper
• Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

  2017cites this paper
• Pharmacogenomics of Primary Blood Cancer Cells

  2017cites this paper
• B-Raf Inhibition in the Clinic: Present and Future.

  2016cites this paper
• Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

  2016cites this paper
• Contemporary and potential future molecular diagnosis of melanoma

  2016cites this paper
• (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges

  2016cites this paper
• The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

  2016cites this paper
• The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock

  2016cites this paper